Class ITerminatedD-0765-2022
Drug recall · April 20, 2022
IDArubicin Hydrochloride Injection USP 5gm/5mL recall
Why: Presence of Particulate Matter: Product was found to contain silica and iron oxide
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11.
- Lots / codes
Lot #: 31329657B, Exp. Date 08/2023
- Quantity
- 1565 vials
- Company
- Teva Pharmaceuticals USA Inc, Parsippany, NJ
- Distribution
- Nationwide within the United States
- Initiated
- March 29, 2022 · Voluntary: Firm initiated
- Classified
- April 11, 2022
- Reported
- April 20, 2022
- Ended
- June 20, 2023
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.